Tauriga Sciences Inc. Completes Payment for the Entirety of its Recently Announced - Largest Tauri-Gum Production Run in Company History
Tauriga Sciences, Inc. (OTCQB: TAUG) announced the completion of its largest Tauri-Gum™ production run, investing $267,500 to manufacture 70,000 – 72,000 blister packs across 8 distinct flavors. Each piece of gum contains 25mg of CBD or CBG. The product line is Kosher and Halal certified, vegan, and made in the USA, catering to the growing CBD and CBG edibles market. The company also has a pharmaceutical development initiative aimed at creating a medication-grade version of Tauri-Gum™ for chemotherapy patients.
- Completed largest production run, improving product availability.
- Investment of $267,500 indicates strong business commitment.
- Tauri-Gum™ is diversified with 8 unique flavors, appealing to various consumer tastes.
- All products are Kosher, Halal, and vegan, broadening market reach.
- None.
This Production Run Incorporates the Increased CBD & CBG Infusion Concentrations (25mg per Each Piece of Chewing Gum)
NEW YORK, NY, March 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has completed payment for the entirety of its recently announced, largest Tauri-Gum™ production run in Company history. The Company paid a total of
1) 8,750 – 9,000 Tauri-Gum™ Blister Packs
25mg CBD Infused / Pomegranate Flavor
2) 8,750 – 9,000 Tauri-Gum™ Blister Packs
25mg CBD Infused / Blood Orange Flavor
3) 8,750 – 9,000 Tauri-Gum™ Blister Packs
25mg CBG Infused / Peach-Lemon Flavor
4) 8,750 – 9,000 Tauri-Gum™ Blister Packs
60mg Vitamin C + 10mg Zinc / Pear Bellini Flavor
5) 8,750 – 9,000 Tauri-Gum™ Blister Packs
25mg CBD Infused / Mint Flavor
6) 8,750 – 9,000 Tauri-Gum™ Blister Packs
25mg CBG Infused / Black Currant Flavor
7) 8,750 – 9,000 Tauri-Gum™ Blister Packs
50mg Caffeine Infused / Cherry Lime Rickey Flavor
8) 8,750 – 9,000 Tauri-Gum™ Blister Packs
2,000 IUs Vitamin D3 Infused / Golden Raspberry Flavor
The Company’s proprietary Tauri-Gum™ product line is comprised of 8 distinct Versions (5 of which are cannabinoid infused / 3 of which are cannabinoid-free). This product line is: Kosher Certified (Authority: Star-K), Halal Certified (Authority: Etimad), Vegan Formulated, Non-GMO, Gluten Free, Allergen Free, All-Natural Flavors, Lab Tested, No-THC,
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Attachment
FAQ
What is the latest Tauri-Gum™ production run by Tauriga Sciences (TAUG)?
How much did Tauriga Sciences invest in the Tauri-Gum™ production run?
What concentrations are included in the new Tauri-Gum™ products by TAUG?
What makes Tauri-Gum™ appealing to consumers?
Is Tauriga Sciences involved in pharmaceutical development?
